House Committee Says J&J Is Dragging Its Heels On Recall Probe : Shots - Health News A House panel says Johnson & Johnson hasn't been cooperative enough on an investigation of quality problems with medicines. The company disagrees.
NPR logo House Committee Says J&J Is Dragging Its Heels On Recall Probe

House Committee Says J&J Is Dragging Its Heels On Recall Probe

Two weeks after a contentious Capitol Hill hearing into Johnson & Johnson's quality problems with children's medicine, the chairman of a House panel says the company is hindering the investigation.

One of the medicines for children that Johnson & Johnson recalled in April. J&J hide caption

toggle caption
J&J

Rep. Edolphus Towns (D-NY) told the New York Times that J&J hadn't been forthcoming with the committee's investigation.

Other companies probed recently by the panel, including Bank of America and AIG, did a better job, he told the paper. "But we are not getting the kind of information and cooperation from Johnson that I would like," Towns told the Times.

In an e-mail to Shots, Bonnie Jacobs, a spokeswoman for J&J's McNeil unit, disputed that characterization:

We have been very cooperative with the Committee. We have provided about 20,000 pages of documents to the Committee. Every executive that the Committee asked to interview has been made available.

A spokeswoman for the House Committee on Oversight and Government Reform told us the "Chairman's comments stand."

At issue is how the company handled quality problems at a plant that made liquid medicines for kids, including Tylenol and Benadryl, and were recalled in late April. Another line of questioning concerns the company's handling of problems with adult-strength Motrin tablets and what the committee called a "phatom recall" of the medicines.